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Cutaneous Polyarteritis Nodosa (cPAN) was first described in 1931. cPAN is considered a rare disease, its true
incidence is unknown. The age of onset is diverse. Most studies have shown no significant gender predominance.
cPAN presents with distinct skin findings, such as a maculopapular rash, subcutaneous nodules, livedoid vasculitis,
panniculitis, ischemic finger lesions, or erythematous patchy rash.
Etiology is unclear. It is still believed to be an immune complex-mediated disease, although a possible mechanism
recently proposed relates a familial form of the disease to impaired activity of Adenosine Deaminase 2. cPAN may
reflect an underlying disease, infection or medical treatment.
There is no consensus as to initial treatment, dosage and length of treatment. Patients with constitutional
symptoms, visceral involvement, a more severe course of the disease, or high acute phase reactants, were treated
mainly with systemic corticosteroids and/or cytotoxic agents for varying durations. However, persistence of
cutaneous lesions has been documented.
We describe a 14 year old male suffering from persistent cPAN, with no constitutional symptoms or involvement
of internal organs. The patient was treated with a local corticosteroid-based ointment during exacerbations, until
complete remission. Although reported in only one study, treatment with topical corticosteroid compound may
result in significant improvement or complete regression of skin lesions in cPAN patients.
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valerateBackground
The first description of limited cutaneous polyarteritis
nodosa (cPAN) was published by Lindberg in 1931, de-
scribing skin findings, and also extra-cutaneous findings,
such as fever, malaise, myalgia, arthralgia and neuropathy
(unlike systemic PAN, in which the cutaneous findings are
only secondary to internal organs involvement, mainly
kidney, heart & liver) [1].
cPAN is rare; its true incidence is unknown. It is esti-
mated that one third of children diagnosed with systemic
PAN (sPAN), actually have cPAN [2,3], but in practice,
rheumatologists may treat more cPAN patients than sPAN
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unless otherwise stated.Age of onset ranges from the neonatal and infantile
period [4,5], up to age 81 [6]. Most studies do not reveal
any significant gender predominance [1]. A male to female
ratio of 1:1.7 was found in a large study of 79 cases [6].
cPAN presents with distinct skin findings, such as a
maculopapular rash, subcutaneous nodules, livedoid
vasculitis, panniculitis, ischemic finger lesions, or ery-
thematous patchy rash. In a study of juvenile polyarteritis,
all patients with cPAN were diagnosed with necrotizing
arterial inflammation found on biopsy [3].
The etiology of cPAN is unknown. It is, most probably,
an immune complex-mediated disease, with some evidence
of serum IgM anti-phosphatidylserine-prothrombin anti-
bodies in patients’ sera, and deposition of C3 within vessel
walls, as shown by direct immunofluorescence techniques
[7]. Recently, loss-of-function mutations, in the gene
(CECR1) encoding Adenosine Deaminase 2, were foundtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 A lower extremity nodular lesion.
Figure 2 The photos capture a lower extremity necrotic lesion in
different stages of skin involvement.
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one participant of Georgian ancestry in this study did
not present with any cutaneous features, while visceral
involvement was described in about half of the participants.
The suggested mechanism is related to the chronically high
levels of adenosine, or an impaired ADA2 function as a
growth factor [5].
cPAN may reflect an underlying disease (ie inflamma-
tory bowel disease [6]), infection (ie Hepatitis B virus,
although findings were not consistent), or medications
[1]. The most common agent identified is Group A β
hemolytic Streptococcus.
There is no consensus as to initial treatment, dosage
and length of treatment. However, in some studies, in
which cPAN was found to be associated with a Strepto-
coccal infection, prophylaxis with penicillin was initiated
[1,3,8,9]. Patients with constitutional symptoms, visceral
involvement, a more severe course of the disease, or high
acute phase reactants, were treated mainly with systemic
corticosteroids, cyclophosphamide and/or azathioprine for
varying durations [3]. If the patient was non-responsive,
other studies reported IVIg [10,11], colchicine, hydroxy-
chloroquine, dapsone, methotrexate, sulphapyridine and
pentoxifylline [1,3,6] as alternative treatments. Mild cases,
consisting of mainly skin lesions, were treated with
non-steroidal anti-inflammatory drugs or cholchicine.
To date, only one case report investigating topical
treatment for cPAN, among adult patients, has been
published [12]. Persistence of cutaneous lesions has
been documented. Rarely, did it progress to PAN.
Case presentation
We present a 14 year old male, who had been suffering
from cutaneous skin lesions, for 2 years prior to diagnosis.
No other complaints or symptoms, such as fever, weight
loss, arthritis, arthralgia, myalgia or hypertension were
reported.
His past medical history was unremarkable, except for
a milk allergy.
Family background: Both parents are Jewish, mother’s
family from Eastern Europe; father’s family from Egypt.
There were no reported rheumatologic or autoimmune
diseases.
Physical examination was unremarkable, except for the
nodular and tender skin lesions. The primary lesions were
maculopapular, which had gradually evolved to tender and
locally warm nodular skin lesions, later becoming nec-
rotic. Trunk and extremities were involved (Figures 1, 2
capture lower extremity lesions in different stages of skin
involvement), in addition to the patient’s face and right
eyelid (Figures 3, 4, 5, 6 show the natural history of a right
eyelid necrotizing lesion).
Laboratory workup, including acute phase reactants,
complete blood count, liver and kidney function testsand urinalysis, were within normal ranges. Comprehensive
infectious work-up was negative. Autoantibodies, includ-
ing anti-nuclear antibodies, anti double-stranded DNA anti-
bodies, and rheumatoid factor, were negative. Complement
factors were normal. pANCA, cANCA, anti-myelperoxidase
and anti-proteinase 3 antibodies, anti-Saccharomyces cer-
evisiae antibodies and antiphospholipid antibodies were
all negative. Immunoglobulin profile was normal. Anti-
Streptolysin O and anti-DNAse B antibodies were not de-
tected. Hepatitis virus antibodies were negative. A whole
blood sample was analyzed for common Familial Mediter-
ranean Fever (FMF) mutations. The results were negative.
Abdominal ultrasound, including Doppler imaging of
the renal arteries, chest x-ray and echocardiogram were
all normal.
Skin biopsies were taken in another hospital, but the
slides were re-examined in our hospital. Skin tissue sam-
ples showed widespread panniculitis and necrotizing
medium vessel vasculitis, with fibrinoid necrosis, com-
patible with polyarteritis nodosa.
Since there were no indications of systemic involvement,
based on the patient’s medical history, physical examin-
ation and laboratory results, he was diagnosed with cPAN.
Figure 3 The natural history of a right eyelid necrotizing lesion –
early stage.
Figure 5 The natural history of a right eyelid necrotizing
lesion – necrosis.
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Mainly concerned about the side effects of systemic
steroidal treatment, the parents refused to any sys-
temic treatment (including other oral agents, such as
colchicine), relying on the boy’s good appearance and
well-being. The patient was thus treated with topical
diflucortolone valerate during exacerbations, three times a
day, for two to three weeks at a time, until complete
remission. Both facial and trunk lesions were treated,
without any recurrence of a specific treated lesion
reported during follow-up visits. If a lesion was not treated
within days of its appearance, it would have become nec-
rotic. No adverse reactions were reported, no extensive
skin atrophy was marked, and no cataract was diagnosed
upon follow-up. A lesion became infected only once (by
Staphylococcus aureus and Pseudomonas aeruginosa), and
was successfully treated with oral antibiotics.Figure 4 The natural history of a right eyelid necrotizing
lesion – progression.Conclusions
Currently, there is no consensus as to initial treatment,
dosage and length of treatment in cPAN patients. We
describe herein a 14 year old male, diagnosed with cPAN.
Due to parental refusal to any systemic treatment, he was
treated with a topical corticosteroid-based compound
during exacerbations, applying the compound three
times a day, for two to three weeks at a time. Treatment
was very effective, resulting in a complete remission,
without any recurrence or adverse effect documented
during follow-up. If the compound had been applied
after a few days delay, the lesion would have become
necrotic. Topical corticosteroid compounds may be ef-
ficient in treating isolated skin lesions among cPAN
patients, without mucosal or systemic signs of involve-
ment. This is the first published case utilizing an ef-
fective topical treatment among juvenile patients. A
prospective, multi-center study should be conducted,
to evaluate different available treatments available, and
weigh the different approaches in the light of the long-term
adverse effects.Figure 6 The natural history of a right eyelid necrotizing
lesion – healing.
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